Literature DB >> 21317220

Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction.

Bjørn Olav Åsvold1, Lars J Vatten, Pål R Romundstad, Pål A Jenum, S Ananth Karumanchi, Anne Eskild.   

Abstract

Maternal angiogenic factors (placental growth factor, soluble fms-like tyrosine kinase 1 (Flt-1), and soluble endoglin) may be associated with fetal growth restriction, and the associations may differ according to stage of pregnancy. Among children born to pregnant women without preeclampsia in Norway between 1992 and 1994, 217 singletons with severe growth restriction (small for gestational age (SGA), <2.5th percentile) were compared with 378 singleton controls. For each angiogenic factor, SGA risk was related to concentrations in maternal serum collected in the first 2 trimesters, by using women with a serum concentration in the middle third at both samplings as reference. A low placental growth factor (lowest third) at both samplings was associated with high risk of SGA (odds ratio=3.8, 95% confidence interval: 1.6, 8.8). An increase from the lowest to the highest third of soluble Flt-1 was associated with high SGA risk (odds ratio=6.2, 95% confidence interval: 2.4, 16.1). Women with high soluble endoglin (highest third) at the second sampling had approximately a 3.5-fold increased risk of SGA. Low maternal soluble Flt-1 in early pregnancy followed by a strong subsequent increase in soluble Flt-1 and soluble endoglin was associated with a particularly high risk of severe fetal growth restriction.
© The Author 2011. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317220     DOI: 10.1093/aje/kwq373

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  22 in total

1.  Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

Authors:  Mimi Y Kim; Jill P Buyon; Marta M Guerra; Sarosh Rana; Dongsheng Zhang; Carl A Laskin; Michelle Petri; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Joan T Merrill; Mary D Stephenson; Qi Gao; S Ananth Karumanchi; Jane E Salmon
Journal:  Am J Obstet Gynecol       Date:  2015-09-29       Impact factor: 8.661

2.  Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; James H Segars; Alan H DeCherney; M Cathleen McCoy; Chong Jai Kim; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2015-04-20

3.  Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

Authors:  Steven J Korzeniewski; Roberto Romero; Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo
Journal:  Am J Obstet Gynecol       Date:  2015-12-11       Impact factor: 8.661

4.  Prediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women.

Authors:  Shin Takenaka; Walter Ventura; Anna Freni Sterrantino; Akihiro Kawashima; Keiko Koide; Kyoko Hori; Antonio Farina; Akihiko Sekizawa
Journal:  Reprod Sci       Date:  2014-12-09       Impact factor: 3.060

5.  The placenta in preeclampsia.

Authors:  James M Roberts; C Escudero
Journal:  Pregnancy Hypertens       Date:  2012-04-01       Impact factor: 2.899

6.  Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Juan Pedro Kusanovic; Eleazar Soto; Jennifer Lam; Zhong Dong; Nandor G Than; Lami Yeo; Edgar Hernandez-Andrade; Agustín Conde-Agudelo; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2013-01-17       Impact factor: 8.661

7.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

8.  Maternal concentrations of human chorionic gonadotropin (hCG) and risk for cerebral palsy (CP) in the child. A case control study.

Authors:  Anne Eskild; Lars Monkerud; Anne Marie Jukic; Bjørn Olav Åsvold; Kari Kveim Lie
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-07-04       Impact factor: 2.435

9.  Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania.

Authors:  Anne Marie Darling; Chloe R McDonald; Andrea L Conroy; Kyla T Hayford; W Conrad Liles; Molin Wang; Said Aboud; Willy S Urassa; Kevin C Kain; Wafaie W Fawzi
Journal:  Am J Obstet Gynecol       Date:  2014-05-29       Impact factor: 8.661

10.  Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.

Authors:  Renée S Mijal; Claudia B Holzman; Sarosh Rana; S Ananth Karumanchi; Jianling Wang; Alla Sikorskii
Journal:  J Matern Fetal Neonatal Med       Date:  2011-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.